These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 19221985)

  • 41. Inspection of clinical investigations by the German health authorities.
    Schmidt M
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):229-31. PubMed ID: 8361260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Views of the process and content of ethical reviews of HIV vaccine trials among members of US institutional review boards and South African research ethics committees.
    Klitzman R
    Dev World Bioeth; 2008 Dec; 8(3):207-18. PubMed ID: 19046258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
    Englev E; Petersen KP
    Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The inspection by the Danish Medical Products Agency of drug clinical trials].
    Jacobsen E; Stilbo I
    Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Institutional review boards (IRBs) would have an increased role in international research.
    Maloney DM
    Hum Res Rep; 2002 Oct; 17(10):9. PubMed ID: 12731498
    [No Abstract]   [Full Text] [Related]  

  • 46. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
    Tuffs A
    BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
    [No Abstract]   [Full Text] [Related]  

  • 47. [Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany].
    Vollmar HC; Georgieff P; Bührlen B
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):738-43. PubMed ID: 21147437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Drug research in Germany--problems and chances--from the viewpoint of the drug industry].
    Weihrauch TR; Baumbauer E
    Arzneimittelforschung; 1998 Nov; 48(11):1047-50. PubMed ID: 9850422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinician educators' experiences with institutional review boards: results of a national survey.
    Dyrbye LN; Thomas MR; Papp KK; Durning SJ
    Acad Med; 2008 Jun; 83(6):590-5. PubMed ID: 18520468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Research subject complains about how she was treated by an institutional review board (IRB).
    Maloney DM
    Hum Res Rep; 2005 Dec; 20(12):7. PubMed ID: 16607709
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical trials bureaucracy: unintended consequences of well-intentioned policy.
    Califf RM
    Clin Trials; 2006; 3(6):496-502. PubMed ID: 17170032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Compassionate use of non-approved medicinal products. Legal basis and guidelines].
    Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):439-43. PubMed ID: 19343282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case study: research subject says institutional review board (IRB) was no help.
    Maloney DM
    Hum Res Rep; 2006 Jan; 21(1):7. PubMed ID: 16789306
    [No Abstract]   [Full Text] [Related]  

  • 54. Pediatric psychopharmacological research in the post EU regulation 1901/2006 era.
    Schmäl C; Becker K; Berg R; Brünger M; Lehmkuhl G; Oehler KU; Ruppert T; Staudter C; Trott GE; Dittmann RW
    Z Kinder Jugendpsychiatr Psychother; 2014 Nov; 42(6):441-9. PubMed ID: 25335522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review of multicenter studies by multiple institutional review boards: characteristics and outcomes for perinatal studies implemented by a multicenter network.
    Abramovici A; Salazar A; Edvalson T; Gallagher N; Dorman K; Tita A;
    Am J Obstet Gynecol; 2015 Jan; 212(1):110.e1-6. PubMed ID: 25088862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Zealand law's protection of drug trial participants.
    McGettigan J
    J Law Med; 2009 May; 16(5):885-90. PubMed ID: 19554866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].
    Riedel C; Lehmann B; Broich K; Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Dec; 59(12):1587-1592. PubMed ID: 27778087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The pediatric drug initiative].
    Krankenpfl J; 2005; 43(7-10):218-9. PubMed ID: 16515290
    [No Abstract]   [Full Text] [Related]  

  • 59. [Changes in the German Medicinal Product Act imposed by the EU regulation on clinical trials].
    Nickel L; Seibel Y; Frech M; Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):804-811. PubMed ID: 28664271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving balance in regulatory oversight of research in children and adolescents: a clinical investigator's perspective.
    Rosenfield RL
    Ann N Y Acad Sci; 2008; 1135():287-95. PubMed ID: 18574235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.